Prognostic value of inflammatory markers in predicting recurrence-free survival in gastrointestinal stromal tumor patients: A nomogram-based approach

Figure 1 Receiver operating characteristic curve for systemic immune-inflammation index, neutrophil/lymphocyte ratio, monocyte/ lymphocyte ratio, platelet/lymphocyte ratio. A: Systemic immune-inflammation index receiver operating characteristic curve; B: Neutrophil/lymphocyte ratio receiver operating characteristic curve; C: Monocyte/lymphocyte ratio receiver operating characteristic curve; D: Platelet/lymphocyte ratio receiver operating characteristic curve. SII: Systemic immune-inflammation index; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratio; ROC: Receiver operating characteristic.

Figure 2 Recurrence-free survival curves for monocyte/Lymphocyte ratio, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, systemic immune-inflammation index and targeted therapy. A: Systemic immune-inflammation index; B: Neutrophil/lymphocyte ratio; C: Monocyte/lymphocyte ratio; D: Platelet/lymphocyte; E: Targeted therapy. SII: Systemic immune-inflammation index; NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratio; RFS: Recurrence-free survival.

Figure 3 The nomogram for platelet/lymphocyte ratio, monocyte/lymphocyte ratio, and postoperative targeted therapy. PLR: Platelet/ lymphocyte ratio; MLR: Monocyte/lymphocyte ratio; RFS: Recurrence-free survival.